Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis

Australasian Journal of Dermatology

Volumn 54, Issue 4, 2013, Pages 259-263

  Tan, Eugene ^a   Baker, Christopher ^a,b,c   Foley, Peter ^a,b,c  

^a SKIN AND CANCER FOUNDATION   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

adalimumab; anti TNF ; biologics; body mass index; etanercept; infliximab; PASI75; psoriasis; ustekinumab

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PSORIASIS; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

ADALIMUMAB; ANTI-TNFΑ; BIOLOGICS; BODY MASS INDEX; ETANERCEPT; INFLIXIMAB; PASI75; PSORIASIS; USTEKINUMAB;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BODY MASS INDEX; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

EID: 84886777788     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/ajd.12044     Document Type: Article

References (36)

1. Australian Institute of Health and Welfare. Australia's Health 2004. (2004). Available from URL: http://www.aihw.gov.au/publication-detail/?id= 6442467608 (Accessed 5 March 2013).
2. Huerta C, Rivero E, Rodriguez LA,. Incidence and risk factors for psoriasis in the general population. Arch. Dermatol. 2007; 143: 1559-1565.
3. Naldi L,. Epidemiology of psoriasis. Curr. Drug Targets Inflamm. Allergy 2004; 3: 121-128.
4. Woodley DT, Kim GH,. Potential new insight into the pathogenesis of psoriasis. Arch. Dermatol. 2009; 145: 713-714.
5. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 2004; 51: 534-542.
6. Iyer S, Yamauchi P, Lowe NJ,. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br. J. Dermatol. 2002; 146: 118-121.
7. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 2003; 349: 2014-2022.
8. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
9. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin. Ther. 2003; 25: 1700-1721.
10. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br. J. Dermatol. 2008; 158: 558-566.
11. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
12. Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch. Dermatol. 2009; 145: 700-703.
13. Friedewald VE, Cather JC, Gelfand JM, et al. AJC editor's consensus: psoriasis and coronary artery disease. Am. J. Cardiol. 2008; 102: 1631-1643.
14. Qureshi AA, Choi HK, Setty AR, et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch. Dermatol. 2009; 145: 379-382.
15. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br. J. Dermatol. 2007; 156: 271-276.
16. Gisondi P, Cotena C, Tessari G, et al. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J. Eur. Acad. Dermatol. Venereol. 2008; 22: 341-344.
17. Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol. Res. 2008; 57: 290-295.
18. Stamp L, Cross N, O'Donnell J,. Weight gain with tumour necrosis factor-alpha inhibitors. Intern. Med. J. 2005; 35: 267.
19. Mahe E, Reguiai Z, Barthelemy H, et al. Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study. J. Eur. Acad. Dermatol. Venereol. 2012; doi: 10.1111/jdv.12066. [Epub ahead of print].
20. Florin V, Cottencin AC, Delaporte E, et al. Body weight increment in patients treated with infliximab for plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 2013; 27: e186-190.
21. Briot K, Gossec L, Kolta S, et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J. Rheumatol. 2008; 35: 855-861.
22. Engvall IL, Tengstrand B, Brismar K, et al. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomized study over 21 months. Arthritis Res. Ther. 2010; 12: R197.
23. Koutroubakis IE, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2009; 21: 283-288.
24. Parmentier-Decrucq E, Duhamel A, Ernst O, et al. Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. Inflamm. Bowel Dis. 2009; 15: 1476-1484.
25. Walsmith J, Roubenoff R,. Cachexia in rheumatoid arthritis. Int. J. Cardiol. 2002; 85: 89-99.
26. Roubenoff R, Roubenoff RA, Ward LM, et al. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J. Rheumatol. 1992; 19: 1505-1510.
27. Nishida K, Okada Y, Nawata M, et al. Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocr. J. 2008; 55: 213-216.
28. Del Porto F, Lagana B, Lai S, et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1111-1115.
29. Kiortsis DN, Mavridis AK, Filippatos TD, et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol. 2006; 33: 921-923.
30. Yazdani-Biuki B, Stelzl H, Brezinschek HP, et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur. J. Clin. Invest. 2004; 34: 641-642.
31. Seriolo B, Ferrone C, Cutolo M,. Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J. Rheumatol. 2008; 35: 355-357.
32. Oguz FM, Oguz A, Uzunlulu M,. The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. Acta Clin. Belg. 2007; 62: 218-222.
33. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 2006; 24: 83-86.
34. Huvers FC, Popa C, Netea MG, et al. Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases. Ann. Rheum. Dis. 2007; 66: 558-559.
35. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668.
36. Wilson PW, Kannel WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch. Intern. Med. 1999; 159: 1104-1109.